3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

425 - Onconetix, Inc. (0001782107) (Subject)

425 - Onconetix, Inc. (0001782107) (Subject)

DEF 14A - Onconetix, Inc. (0001782107) (Filer)

425 - Onconetix, Inc. (0001782107) (Subject)

8-K/A - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

PRE 14A - Onconetix, Inc. (0001782107) (Filer)

10-K - Onconetix, Inc. (0001782107) (Filer)

425 - Onconetix, Inc. (0001782107) (Subject)

8-K - Onconetix, Inc. (0001782107) (Filer)

SC 13G - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Onconetix, Inc. (0001782107) (Subject)

SC 13G - Onconetix, Inc. (0001782107) (Subject)

SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and

Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company's Board of Directors and the Audit Committee, effective March 19, 2026. Karina Fedasz, the Company's outgoing Interim Chief Executive Officer, will continue to serve as its Interim Chief Financial Officer. These appointments reflect the Company's commitment to assembling experien

CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026. On February 3, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect a reverse split, at a ratio in

A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America  CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech Inc), and Realbotix LLC. ("Realbotix"), a wholly-owned subsidiary of Realbotix Corp. (TSXV:XBOT) ("Realbotix Parent "), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction. Realbotix LLC is Realbotix Corp's subsidiary that is focused on researching, designing, bu

Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Parent Company"), a leader in AI-powered humanoid robots, announces it has entered into a definitive agreement with Onconetix, Inc (NASDAQ:ONCO) ("ONCO"), pursuant to which ONCO will acquire 100% of Realbotix, LLC ("RealLLC" or the "Subsidiary"), a wholly owned subsidiary of Realbotix in an all-stock transaction. RealLLC is a Nevada based wholly owned subsidiary of Realbotix. RealLLC focuses on the research, development, design and manufacture of AI-powered humanoid robots for use by commercial clients in consumer facing roles such as customer service, healthcare, education, hospitality and entertainment. Rea

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop

CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million

CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and deliver

CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden. Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property

CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the "Merger Agreement"). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ophthalmic assets, will bring significant value for our stockholders." Anthony W. Amato, Chairman and CEO of Ocuvex, commented